Nano
-
- USD 5.99
-
- USD 5.99
Descripción editorial
A lavishly funded, security-conscious nanotechnology institute in the foothills of the Rockies, Nano is ahead of the curve in the competitive world of molecular manufacturing, including the construction of microbivores, tiny nanorobots with the ability to gobble up viruses and bacteria.
But when Pia Grazdani takes a job there, she’s shocked by the secretive corporate culture. She’s warned by her boss not to investigate the other work being done at the gigantic facility, nor to ask questions about the source of the seemingly endless capital that funds the institute’s research. And when Pia encounters a fellow employee on a corporate jogging path suffering the effects of a seizure, she soon realizes she may have literally stumbled upon Nano’s human guinea pigs. Is the tech giant on the cusp of one of the biggest medical discoveries of the twenty-first century—a treatment option for millions—or have they already sold out to the highest bidder?
PUBLISHERS WEEKLY
This accomplished if familiar medical thriller from bestseller Cook picks up the story of doctor-to-be Pia Grazdani after her horrific experiences in 2011's Death Benefit, which included being abducted and witnessing a colleague, Will McKinley, being shot in the head. Pia decides to defer her New York City residency in favor of taking a position with Nano, a Boulder, Colo., company on the cutting edge of nanotechnology research. Nano's development of "a microbivore-based antibacterial treatment" may help Will recover. To no reader's surprise, Nano's stereotypical evil businessman/scientist head, Zachary Berman, is prepared to jump across experimental ethics lines in pursuit of his own ends. Though Berman's company finds a way to enable "a man to survive a massive, normally lethal medical crisis apparently unharmed," Pia suspects that something more sinister is in the works. The concept of a young medico stumbling on a deadly conspiracy may have been fresh in 1977's Coma, but more than three decades later, there isn't much novelty left.
